Course Director John G Bartlett, MD, Johns Hopkins University School of Medicine
11:00 AM: New Paradigms for the Treatment of Patients Infected with HCV Genotype 1:
Peginterferon Alfa/Ribavirin Combined With HCV Protease Inhibitors
Mark S. Sulkowski, MD, Johns Hopkins University School of Medicine
1:00 PM: Maximizing Success and Minimizing Risks: The Role of IL28B Testing and Hepatitis C Viral Kinetics
Andrew J. Muir, MD, MHS, Duke University School of Medicine
David L. Thomas, MD, MPH, Johns Hopkins University School of Medicine
2:00 PM: Successful Office-Based Management of Patients With HCV Protease Inhibitors and Peginterferon/Ribavirin
K. Rajender Reddy, MD, University of Pennsylvania Perelman School of Medicine
Sanjeev Aurora, MD, University of New Mexico Health Science Center
Mark S. Sulkowski, MD, Johns Hopkins University School of Medicine
3:00 PM: The Treatment of Challenging HCV-Infected Patients
David L. Thomas, MD, MPH, Johns Hopkins University School of Medicine
Webinar available until 11/16/12
